============================= ==============
BERNAMA .com
News in Brief
29 July 2021
===========================
Nylex ( Malaysia ) Berhad /4944
ABOUT US CORPORATE PROFILE
Nylex (Malaysia) Berhad ("Nylex") is a public limited liability company, incorporated and domiciled in Malaysia and listed on the Main Market of Bursa Malaysia Securities Berhad in 1990.
Today, it has emerged as a dominant player in the petrochemicals, industrial and specialty chemicals, plastics and polymers business with an annual turnover of more than RM1.3 billion and over 16 subsidiaries operating mainly in Malaysia, Singapore, Indonesia and Vietnam.
Nylex is principally involved in investment holding and the manufacturing and marketing of vinyl-coated fabrics, calendered film and sheeting, rotomoulded plastic products, and other plastic products, including geotextiles, prefabricated sub-soil drainage systems, bulk chemical containers, road barriers, playground equipment and disposal bins.
Nylex's subsidiaries involved in distribution, trading, manufacturing and sale of petrochemicals and industrial chemical products and manufacture and marketing of polyvinyl chloride (more commonly known as PVC) and polyurethane ("PU") synthetic leather, films and sheets and carrying out business of transport, cartage and haulage contractors and agencies, ship owning, ship management and charter hire of tanker.
Nylex's products are widely sold to Europe, the Middle East, Africa more than 15 countries in Asia Pacific including Oceania.
===========================
Ancom posts best results since 2008 with RM23.9m FY21 net profit
KUALA LUMPUR, July 30 — Ancom Berhad recorded strong fourth quarter and full-year financial results for the period ended May 31, 2021 amid a highly challenging operating environment.
In a statement, the leading manufacturer and supplier of agricultural and industrial chemicals in South-east Asia said its 4QFY21 revenue increased 44.1 per cent year-on-year to RM445.9 million compared to RM309.4 million in the same period last year.
It said the improvement was primarily driven by the agricultural chemicals segment as higher global demand bolstered the segmental top line by 28.6 per cent to RM79.9 million.
Higher trading volume and average selling prices also boosted the revenue of the industrial chemicals arm by 52.6 per cent y-o-y to RM325.1 million, the group added.
Ancom’s profit after tax and non-controlling interest also jumped to RM7.6 million in 4QFY21 versus a loss of RM11.8 million a year ago.
For the full year, Ancom’s revenue increased marginally by 4.5 per cent y-o-y to RM1.54 billion in FY21.
Meanwhile,
the Group reported full-year net profit of RM23.9 million for FY21, which Ancom Berhad Group CEO Lee Cheun Wei noted was its best full-year bottom line since 2008.
“Our agricultural chemicals division has done very well, riding on the uptrend of global demand for food. We anticipate the trend to persist with a continued strong contribution from this segment. As for the industrial chemicals segment, our trading business has performed favourably too, having benefited from higher sales volume and generally higher average selling prices,” he said.
Given the restrictions in operations imposed during MCO/EMCO in the months of June and July, we have been very vigilant to comply with regulations while continuing to serve our clients as an integral part of the food supply chain. We are cognisant of the ongoing challenges such as freight costs and supply chain disruptions due to the pandemic, and we managed to deliver commendable results thus far.”
Lee added that he anticipates the growth trajectory of the Group, particularly the agricultural chemicals division, to remain strong.
“Recently, we have begun our production of new active ingredients at our existing plants and are expecting to add a few more to our portfolio once our new plant is ready by the first half of 2022. We are optimistic and will strive to continue to deliver good and satisfactory results for our shareholders next year,” he concluded.
Related Articles Ancom says Nylex’s board has accepted RM179.3m buyout offer Source: Ancom in bid to fully acquire Nylex Ancom Bhd untung lima kali ganda, meningkat RM9.3 juta
As the World Health Organization (WHO) announced Covid-19 outbreak as a pandemic,
glove stocks naturally became attractive to KLSE investors.
JAKARTA, Indonesia — As many Asian countries battle their worst surge of COVID-19 infections, the slow-flow of vaccine doses from around the world is finally picking up speed, giving hope that low inoculation rates can increase and help blunt the effect of the rapidly spreading delta variant.
With many vaccine pledges still unfulfilled and the rates of infection spiking across multiple countries, however, experts say more needs to be done to help nations struggling with the overflow of patients and shortages of oxygen and other critical supplies.
Some 1.5 million doses of the Moderna vaccine were set to arrive Thursday afternoon in Indonesia, which has become a dominant hot spot with a record high infections and deaths.
The U.S. shipment comes in addition to 3 million other American doses that arrived Sunday, and 11.7 million doses of AstraZeneca that have come in batches since March through the U.N.-backed COVAX mechanism, the last earlier this week.
“It’s quite encouraging,” said Sowmya Kadandale, health chief in Indonesia of UNICEF, which is in charge of the distribution of vaccines provided through COVAX. “It seems now to be, and not just in Indonesia, a race between the vaccines and the variants, and I hope we win that race.”
Many, including the World Health Organization, have been critical of the vaccine inequalities in the world, pointing out that many wealthy nations have more than half of their populations at least partially vaccinated, while the vast majority of people in lower-income countries are still waiting on a first dose.
The International Red Cross warned this week of a “widening global vaccine divide” and said wealthy countries needed to increase the pace of following through on their pledges.
“It’s a shame it didn’t happen earlier and can’t happen faster,” Alexander Matheou, the Asia-Pacific director of the Red Cross, said of the recent uptick in deliveries. “There’s no such thing as too late — vaccinating people is always worth doing — but the later the vaccines come, the more people will die.”
Vietnam, Thailand and South Korea have all imposed new lockdown restrictions over the past week as they struggle to contain rapidly rising infections amid sluggish vaccination campaigns.
In South Korea — widely praised for its initial response to the pandemic that included extensive testing and contact tracing — a shortage in vaccines has left 70% of the population still waiting for their first shot. Thailand, which only started its mass vaccination in early June, is seeing skyrocketing cases and record deaths, and only about 15% of people have had at least one shot. In Vietnam, only about 4% have.
“Parts of the world … are talking about reclaiming lost freedoms such as going back to work, opening the cinemas and restaurants,” Matheou told The Associated Press. “This part of the world is far away from that.”
“Both Moderna and AstraZeneca have been really critical in ramping up these numbers and ensuring that the supplies are available,” said UNICEF’s Kadandale, noting that Indonesia plans to have some additional 208.2 million people vaccinated by year’s end and is giving 1 million shots daily. “Every single dose does make a huge difference.”
Many other countries in the region have vaccination rates far below Indonesia’s for a variety of reasons, including production and distribution issues as well as an initial wait-and-see attitude from many early on when numbers were low and there was less of a sense of urgency.
Some were shocked into action after witnessing the devastation in India in April and May as the country’s health system collapsed under a severe spike in cases that caught the government unprepared and led to mass fatalities.
At the same time, India — a major regional producer of vaccines — stopped exporting doses so that it could focus on its own suffering population.
The U.S. has sent tens of millions of vaccine doses to multiple countries in Asia recently, part of President Joe Biden’s pledge to provide 80 million doses, including Vietnam, Laos, South Korea and Bangladesh. The U.S. plans to donate an additional 500 million vaccines globally in the next year, and 200 million by the end of 2021.
“Indonesia is a critical partner for U.S. engagement in Southeast Asia and the vaccines come without strings attached,” said Scott Hartmann, a spokesman for the U.S. Embassy in Jakarta. “We’re doing this with the object of saving lives and ending the global pandemic, and equitable global access to safe and effective vaccines is essential.”
Earlier in the week, German Foreign Minister Heiko Maas, whose country is one of the largest financial backers of COVAX, accused Russia and China of using their delivery of vaccines for policy leverage.
“We note, in particular with China, that the supply of vaccines was also used to make very clear political demands of various countries,” he said, without providing specific examples.
There are also growing questions about the effectiveness of China’s Sinovac vaccine against the delta variant of the virus.
Thai officials said that booster doses of AstraZeneca would be given to front-line medical personnel who earlier received two doses of Sinovac, after a nurse who received two doses of Sinovac died Saturday after contracting COVID-19.
Sinovac has been authorized by WHO for emergency use but Indonesia also said it was planning boosters for health workers, using some of the newly delivered Moderna doses, after reports that some of the health workers who had died since June had been fully vaccinated with the Chinese shot.
“We have still found people getting severe symptoms or dying even when they are vaccinated,” Pandu Riono, an epidemiologist with the University of Indonesia, said about the Sinovac shot. “It’s only proven that some vaccines are strong enough to face the delta variant — AstraZeneca, Moderna and Pfizer seem capable.”
While the majority of recent deliveries have been American, Japan was sending 1 million doses of AstraZeneca on Thursday each to Indonesia, Taiwan and Vietnam as part of bilateral deals, and Vietnam said it was receiving 1.5 million more AstraZeneca doses from Australia.
The Philippines is expecting a total of 16 million doses in July, including 3.2 million from the U.S. later this week, 1.1 million from Japan, 132,000 of Sputnik V from Russia, as well as others through COVAX.
Japan is also is sending 11 million through COVAX this month to Bangladesh, Cambodia, Iran, Laos, Nepal, Sri Lanka, and others. Canada this week committed an additional 17.7 million surplus doses to the 100 million already pledged through COVAX, which is coordinated by Gavi, a vaccine alliance.
In addition to distributing some donated vaccines, financial contributions to COVAX also help fund the purchase of doses to distribute for free to 92 low or moderate income nations.
Earlier this month, it took blistering criticism from the African Union for how long it was taking for vaccines to reach the continent, which noted that just 1% of Africans are fully vaccinated.
============================== =================
SEE_Research - new report with details on the following corporate exercise by
ANCOM & NYLEX
***** *ANCOM
Ancom is undergoing a major corporate consolidation exercise to house its 2 major business divisions, Agrochem & Industrial Chemical,
under one roof.
Pre-consol:
Own 51% Nylex listed co (with business)
Post-consol:
Own 51% Nylex listed co (without business)
+ 100% of all Nylex business under Ancom
(Note: NOT buying over Nylex shares, only assets and liabilities of Nylex)
NYLEX / 4944
What will the Nylex minority obtain ?
GOOD NEWS
GOOD NEWS
GOOD NEWS
▪️Nylex shares still remaiN
▪️ rewards in cash in RM ***** ( + plus )* rewards in Ancom shares
BE PART OF AN ENLARGED CHEMICAL GROUP THAT OWNS BOTH
INDUSTRIAL CHEMICALS BUSINESS +
AGROCHEM BUSINESS
WHY THERE IS SUCH NEED TO HAVE THIS CORPORATE CONSOLIDATION EXERCISE
NYLEX WAS LOSS-MAKING THE PAST 2 YEARS, BUT PETROCHEMICAL PRICES HAVE PROGRESSIVELY RECOVERED AND
NYLEX IS POISED TO TAKE ADVANTAGE WITH THE POSITIVE UPTREND IN INCREASING REVENUES, WITH PROFITS IN TURNING AROUND
ANCOM DILUTE ONLY 10-11%
(SIMILAR TO DOING PRIVATE PLACEMENTS EXERCISES )
TO CONSOLE 100% PROFIT OF NYLEX
PETROCHEMICAL BUSINESS IS ON THE UPTREND, AS CLEARLY IS EVIDENT IN THE RECENT RESULTS OF PETROCHEM INDUSTRY PLAYERS
(EXAMPLE :
L C TITAN, OTHERS)
ANCOM TO HAVE A RECORD YEAR, FOR PROFIT RETURN - THIS FY21
(ONLY CONSOL 51% OF NYLEX PROFIT).
THE COMING YEAR TO BE EVEN BETTER, EXCITING IN PROFIT GROWTH
(CONSOLIDATION OF 100% OF NYLEX PROFIT).
NYLEX (4944) S
NYLEX (MALAYSIA) BERHAD Summary0.845 ↑
+0.005 (+0.60%)Recent Prices
Date | Open | Range | Close | Change | Volume |
---|---|---|---|---|---|
30/07/2021 | 0.86 | 0.845 - 0.865 | 0.845 | +0.005 (0.60%) | 1,069,100 |
29/07/2021 | 0.84 | 0.835 - 0.84 | 0.84 | 0.00 (0.00%) | 114,000 |
28/07/2021 | 0.835 | 0.835 - 0.85 | 0.84 | +0.005 (0.60%) | 211,200 |
27/07/2021 | 0.84 | 0.835 - 0.845 | 0.835 | -0.005 (0.60%) | 202,200 |
26/07/2021 | 0.835 | 0.83 - 0.855 | 0.84 | 0.00 (0.00%) | 496,900 |
23/07/2021 | 0.835 | 0.835 - 0.84 | 0.84 | 0.00 (0.00%) | 30,600 |
22/07/2021 | 0.84 | 0.83 - 0.845 | 0.84 | +0.005 (0.60%) | 172,800 |
21/07/2021 | 0.84 | 0.825 - 0.84 | 0.835 | -0.005 (0.60%) | 173,700 |
19/07/2021 | 0.84 | 0.83 - 0.84 | 0.84 | 0.00 (0.00%) | 97,200 |
16/07/2021 | 0.835 | 0.83 - 0.84 | 0.84 | +0.005 (0.60%) | 159,500 |
15/07/2021 | 0.83 | 0.825 - 0.835 | 0.835 | +0.005 (0.60%) | 211,600 |
14/07/2021 | 0.83 | 0.83 - 0.845 | 0.83 | -0.01 (1.19%) | 52,600 |
13/07/2021 | 0.855 | 0.83 - 0.855 | 0.84 | -0.01 (1.18%) | 154,500 |
12/07/2021 | 0.83 | 0.825 - 0.85 | 0.85 | +0.02 (2.41%) | 391,700 |
09/07/2021 | 0.83 | 0.83 - 0.835 | 0.83 | 0.00 (0.00%) | 178,400 |
08/07/2021 | 0.84 | 0.83 - 0.84 | 0.83 | -0.01 (1.19%) | 661,900 |
07/07/2021 | 0.845 | 0.84 - 0.855 | 0.84 | -0.005 (0.59%) | 386,400 |
06/07/2021 | 0.85 | 0.845 - 0.855 | 0.845 | -0.005 (0.59%) | 431,300 |
05/07/2021 | 0.87 | 0.845 - 0.87 | 0.85 | -0.015 (1.73%) | 896,600 |
02/07/2021 | 0.85 | 0.845 - 0.865 | 0.865 | +0.015 (1.76%) | 585,500 |
RSI(14) | Neutral 52.2 |
Stochastic(14) | Neutral 50.0 |
Average Volume | 599,000 |
Relative Volume | 1.8 |
Main Market : Chemicals
High | 0.865 |
Low | 0.845 |
Volume | 1,069,100 |
Volume (B/S) | 10,000 / 6,800 |
Price Bid/Ask | 0.845 / 0.850 |
52w | 0.517 - 0.945 |
ROE | 5.71 |
P/E | 9 |
EPS | 9.93 |
DPS | |
DY | 0.00% |
NTA | 1.7400 |
P/B | 0.49 |
RPS | 592.62 |
PSR | 0 |
Market Cap | 164.2M |
Shares (mil) | 194.34 |
TopQ QoQ ConQ YoY | RTopQ RQoQ RConQ RYoY |
RSI(14) | Neutral 52.2 |
Stochastic(14) | Neutral 50.0 |
Average Volume | 599,000 |
Relative Volume | 1.8 |
EPS | DPS | NTA | Revenue | P/L | Quarter | Q Date | Financial Year | Announced | QoQ% | YoY% | Report |
---|---|---|---|---|---|---|---|---|---|---|---|
6.36 | 0.000 | 1.7400 | 353.31m | 11.40m | 4 | 2021-05-31 | 31 May, 2021 | 2021-07-29 | 130.7% | 161% | View |
2.76 | 0.000 | 1.6700 | 289.06m | 4.94m | 3 | 2021-02-28 | 31 May, 2021 | 2021-04-28 | 10.1% | 234.5% | View |
2.56 | 0.000 | 1.7000 | 263.39m | 4.49m | 2 | 2020-11-30 | 31 May, 2021 | 2021-01-26 | 395.5% | 1561.5% | View |
-0.84 | 0.000 | 1.6700 | 245.92m | -1.52m | 1 | 2020-08-31 | 31 May, 2021 | 2020-10-27 | 91.9% | 34.9% | View |
-10.68 | 0.000 | 1.7000 | 230.68m | -18.68m | 4 | 2020-05-31 | 31 May, 2020 | 2020-07-30 | 408.4% | 14467.7% | View |
-2.10 | 0.000 | 1.8400 | 275.34m | -3.67m | 3 | 2020-02-29 | 31 May, 2020 | 2020-05-14 | 1460.7% | 45.6% | View |
0.15 | 0.000 | 1.8700 | 315.72m | 270.00k | 2 | 2019-11-30 | 31 May, 2020 | 2020-01-21 | 124% | 29.2% | View |
-0.63 | 0.000 | 1.8500 | 314.57m | -1.13m | 1 | 2019-08-31 | 31 May, 2020 | 2019-10-29 | 965.4% | 136.5% | View |
0.07 | 1.000 | 1.8300 | 380.28m | 130.00k | 4 | 2019-05-31 | 31 May, 2019 | 2019-07-29 | 101.9% | 97.7% | View |
-3.66 | 1.000 | 1.8100 | 325.31m | -6.75m | 3 | 2019-02-28 | 31 May, 2019 | 2019-04-26 | 3331.1% | 242.5% | View |
0.11 | 0.000 | 1.8600 | 434.36m | 209.00k | 2 | 2018-11-30 | 31 May, 2019 | 2019-01-24 | 93.2% | 97% | View |
1.64 | 0.000 | 1.8600 | 420.40m | 3.08m | 1 | 2018-08-31 | 31 May, 2019 | 2018-10-25 | 45.9% | 87.2% | View |
3.03 | 2.000 | 1.8400 | 424.59m | 5.70m | 4 | 2018-05-31 | 31 May, 2018 | 2018-07-26 | 20.1% | 15.8% | View |
2.51 | 0.000 | 1.8000 | 344.78m | 4.74m | 3 | 2018-02-28 | 31 May, 2018 | 2018-04-30 | 32.4% | 32.7% | View |
3.66 | 0.000 | 1.8200 | 363.36m | 7.01m | 2 | 2017-11-30 | 31 May, 2018 | 2018-01-26 | 326% | 14.9% | View |
0.86 | 0.000 | 1.8100 | 313.64m | 1.65m | 1 | 2017-08-31 | 31 May, 2018 | 2017-10-26 | 75.7% | 250.2% | View |
3.52 | 2.000 | 1.8000 | 380.05m | 6.76m | 4 | 2017-05-31 | 31 May, 2017 | 2017-07-27 | 4% | 4.3% | View |
3.67 | 0.000 | 1.8000 | 369.70m | 7.05m | 3 | 2017-02-28 | 31 May, 2017 | 2017-04-26 | 15.4% | 793.2% | View |
3.18 | 0.000 | 1.7800 | 314.35m | 6.11m | 2 | 2016-11-30 | 31 May, 2017 | 2017-01-25 | 1198.9% | 181.5% | View |
0.24 | 0.000 | 1.6800 | 273.16m | 470.00k | 1 | 2016-08-31 | 31 May, 2017 | 2016-10-26 | 92.8% | 72.5% | View |
3.37 | 2.000 | 1.6800 | 291.02m | 6.49m | 4 | 2016-05-31 | 31 May, 2016 | 2016-07-29 | 721.9% | 189.3% | View |
0.41 | 0.000 | 1.6700 | 256.36m | 789.00k | 3 | 2016-02-29 | 31 May, 2016 | 2016-04-27 | 63.6% | 224.4% | View |
1.13 | 0.000 | 1.6800 | 327.26m | 2.17m | 2 | 2015-11-30 | 31 May, 2016 | 2016-01-29 | 26.8% | 24% | View |
0.89 | 0.000 | 1.6500 | 322.82m | 1.71m | 1 | 2015-08-31 | 31 May, 2016 | 2015-10-28 | 23.7% | 41.5% | View |
1.16 | 2.000 | 1.5600 | 323.79m | 2.24m | 4 | 2015-05-31 | 31 May, 2015 | 2015-07-30 | 453.6% | 341.3% | View |
-0.33 | 0.000 | 1.5500 | 270.60m | -634.00k | 3 | 2015-02-28 | 31 May, 2015 | 2015-04-30 | 122.2% | 121.6% | View |
1.48 | 0.000 | 1.5500 | 319.17m | 2.85m | 2 | 2014-11-30 | 31 May, 2015 | 2015-01-30 | 2.5% | 21.2% | View |
1.52 | 0.000 | 1.5000 | 358.83m | 2.93m | 1 | 2014-08-31 | 31 May, 2015 | 2014-10-23 | 414.9% | 25.3% | View |
-0.48 | 3.000 | 1.5000 | 376.77m | -929.00k | 4 | 2014-05-31 | 31 May, 2014 | 2014-07-25 | 131.7% | 149.7% | View |
1.52 | 0.000 | 1.5100 | 325.70m | 2.93m | 3 | 2014-02-28 | 31 May, 2014 | 2014-04-30 | 19% | 89.8% | View |
1.88 | 0.000 | 1.5000 | 446.60m | 3.62m | 2 | 2013-11-30 | 31 May, 2014 | 2014-01-27 | 55.1% | 68.3% | View |
1.21 | 0.000 | 1.5100 | 416.95m | 2.33m | 1 | 2013-08-31 | 31 May, 2014 | 2013-10-29 | 24.9% | 6.6% | View |
0.97 | 2.000 | 1.4700 | 441.45m | 1.87m | 4 | 2013-05-31 | 31 May, 2013 | 2013-07-31 | 21% | 56.4% | View |
0.80 | 0.000 | 1.4700 | 401.47m | 1.55m | 3 | 2013-02-28 | 31 May, 2013 | 2013-04-30 | 28.2% | 1107% | View |
1.11 | 0.000 | 1.4600 | 444.01m | 2.15m | 2 | 2012-11-30 | 31 May, 2013 | 2013-01-30 | 1.7% | 45.7% | View |
1.13 | 0.000 | 1.4700 | 441.70m | 2.19m | 1 | 2012-08-31 | 31 May, 2013 | 2012-10-29 | 48.9% | 60.2% | - |
2.21 | 2.000 | 1.4700 | 434.71m | 4.29m | 4 | 2012-05-31 | 31 May, 2012 | 2012-07-31 | 3248.4% | 41.1% | - |
0.07 | 0.000 | 1.4100 | 344.53m | 128.00k | 3 | 2012-02-29 | 31 May, 2012 | 2012-04-24 | 96.8% | 96.4% | - |
2.04 | 0.000 | 1.4400 | 380.67m | 3.96m | 2 | 2011-11-30 | 31 May, 2012 | 2012-01-20 | 27.9% | 18.7% | - |
2.83 | 0.000 | 1.4000 | 328.34m | 5.50m | 1 | 2011-08-31 | 31 May, 2012 | 2011-10-25 | 24.5% | 318.1% | - |
3.75 | 2.850 | 1.3900 | 392.01m | 7.28m | 4 | 2011-05-31 | 31 May, 2011 | 2011-07-27 | 105.2% | 54.5% | - |
1.85 | 0.000 | 1.3600 | 295.38m | 3.55m | 3 | 2011-02-28 | 31 May, 2011 | 2011-05-11 | 27.2% | 59.9% | - |
2.59 | 0.000 | 1.4000 | 254.43m | 4.88m | 2 | 2010-11-30 | 31 May, 2011 | 2011-01-25 | 293.5% | 47% | - |
-1.34 | 0.000 | 1.3700 | 284.93m | -2.52m | 1 | 2010-08-31 | 31 May, 2011 | 2010-10-26 | 153.5% | 120.4% | - |
2.50 | 0.000 | 1.4100 | 296.70m | 4.71m | 4 | 2010-05-31 | 31 May, 2010 | 2010-07-30 | 46.8% | 64.1% | - |
4.74 | 0.000 | 1.4000 | 295.53m | 8.85m | 3 | 2010-02-28 | 31 May, 2010 | 2010-04-27 | 3.8% | 437.4% | - |
4.97 | 0.000 | 1.3800 | 297.83m | 9.20m | 2 | 2009-11-30 | 31 May, 2010 | 2010-01-26 | 25.5% | 169% | - |
6.66 | 0.000 | 1.3500 | 332.03m | 12.35m | 1 | 2009-08-31 | 31 May, 2010 | 2009-10-27 | 5.8% | 29.6% | - |
7.07 | 0.000 | 1.2700 | 250.14m | 13.11m | 4 | 2009-05-31 | 31 May, 2009 | 2009-07-31 | 599.8% | 22.9% | View |
-1.45 | 0.000 | 1.2200 | 217.83m | -2.62m | 3 | 2009-02-28 | 31 May, 2009 | 2009-04-30 | 80.3% | 163.5% | View |
-7.55 | 0.000 | 1.3200 | 337.76m | -13.34m | 2 | 2008-11-30 | 31 May, 2009 | 2009-01-22 | 176% | 172.7% | View |
9.94 | 0.000 | 1.3600 | 560.31m | 17.55m | 1 | 2008-08-31 | 31 May, 2009 | 2008-10-29 | 3.2% | 111.7% | View |
9.42 | 4.500 | 1.2300 | 456.69m | 17.00m | 4 | 2008-05-31 | 31 May, 2008 | 2008-07-31 | 311.8% | 145.2% | View |
2.17 | 0.000 | 1.1500 | 375.22m | 4.13m | 3 | 2008-02-29 | 31 May, 2008 | 2008-04-29 | 77.5% | 37% | View |
9.44 | 0.000 | 1.1600 | 476.47m | 18.34m | 2 | 2007-11-30 | 31 May, 2008 | 2008-01-29 | 121.2% | 10.8% | View |
4.27 | 0.000 | 1.0900 | 433.68m | 8.29m | 1 | 2007-08-31 | 31 May, 2008 | 2007-10-30 | 19.6% | 59.4% | View |
3.57 | 2.500 | 1.0700 | 492.07m | 6.94m | 4 | 2007-05-31 | 31 May, 2007 | 2007-07-31 | 5.9% | 229.7% | View |
3.37 | 0.000 | 1.0400 | 391.02m | 6.55m | 3 | 2007-02-28 | 31 May, 2007 | 2007-04-30 | 68.1% | 26.1% | View |
11.63 | 3.000 | 1.0200 | 428.60m | 20.57m | 2 | 2006-11-30 | 31 May, 2007 | 2007-01-23 | 295.3% | 454.7% | View |
2.95 | 0.000 | 0.9600 | 191.00m | 5.20m | 1 | 2006-08-31 | 31 May, 2007 | 2006-10-30 | 147.3% | 46.6% | View |
1.19 | 4.000 | 0.9300 | 178.40m | 2.10m | 4 | 2006-05-31 | 31 May, 2006 | 2006-07-28 | 76.3% | 66.7% | View |
5.02 | 0.000 | 0.9200 | 147.42m | 8.87m | 3 | 2006-02-28 | 31 May, 2006 | 2006-04-14 | 139.2% | 1321.6% | View |
2.10 | 0.000 | 0.8900 | 166.93m | 3.71m | 2 | 2005-11-30 | 31 May, 2006 | 2006-01-26 | 4.5% | 5.8% | View |
2.01 | 0.000 | 0.6900 | 177.55m | 3.55m | 1 | 2005-08-31 | 31 May, 2006 | 2005-10-28 | 43.9% | 37.8% | View |
3.58 | 0.000 | 0.6700 | 192.21m | 6.32m | 4 | 2005-05-31 | 31 May, 2005 | 2005-07-28 | 913% | 146.3% | View |
0.35 | 0.000 | 0.6500 | 147.78m | 624.00k | 3 | 2005-02-28 | 31 May, 2005 | 2005-04-29 | 84.2% | 87.1% | View |
2.23 | 1.200 | 0.6500 | 147.26m | 3.94m | 2 | 2004-11-30 | 31 May, 2005 | 2005-01-31 | 52.9% | 692.4% | View |
1.34 | 0.000 | 0.6200 | 138.25m | 2.58m | 1 | 2004-08-31 | 31 May, 2005 | 2004-10-28 | 118.9% | 25.7% | View |
-6.09 | 0.000 | 0.8100 | 134.83m | -13.66m | 4 | 2004-05-31 | 31 May, 2004 | 2004-07-29 | 382.4% | 349.6% | View |
2.15 | 0.000 | 0.7500 | 77.21m | 4.84m | 3 | 2004-02-29 | 31 May, 2004 | 2004-04-29 | 873.2% | 33.7% | View |
0.22 | 0.000 | 0.7400 | 85.95m | 497.00k | 2 | 2003-11-30 | 31 May, 2004 | 2004-01-28 | 85.7% | 68.2% | View |
1.54 | 0.000 | 0.7600 | 97.21m | 3.47m | 1 | 2003-08-31 | 31 May, 2004 | 2003-10-29 | 36.7% | 42.8% | View |
2.44 | 2.000 | 0.7400 | 109.73m | 5.47m | 4 | 2003-05-31 | 31 May, 2003 | 2003-07-30 | 25% | 76.3% | View |
3.25 | 2.000 | 0.7400 | 94.36m | 7.29m | 3 | 2003-02-28 | 31 May, 2003 | 2003-04-30 | 366.9% | 29.4% | View |
0.70 | 0.000 | 0.7200 | 83.52m | 1.56m | 2 | 2002-11-30 | 31 May, 2003 | 2003-01-29 | 35.7% | 102% | View |
1.08 | 1.000 | 0.7061 | 98.73m | 2.43m | 1 | 2002-08-31 | 31 May, 2003 | 2002-10-31 | 0% | 319.3% | View |
NYLEX / 4944
EPS | DPS | NTA | Revenue | P/L | Quarter | Q Date | Financial Year | Announced | QoQ% | YoY% | Report |
---|---|---|---|---|---|---|---|---|---|---|---|
6.36 | 0.000 | 1.7400 | 353.31m | 11.40m | 4 | 2021-05-31 | 31 May, 2021 | 2021-07-29 | 130.7% | 161% | View |
2.76 | 0.000 | 1.6700 | 289.06m | 4.94m | 3 | 2021-02-28 | 31 May, 2021 | 2021-04-28 | 10.1% | 234.5% | View |
SEE RESEARCH TARGET PRICES
FOR NYLEX:
RM 1.20 to RM 1.30 short term
RM 1.50 mid term
==============================
High | 1.490 |
Low | 1.430 |
Volume | 595,000 |
Volume (B/S) | 1,500 / 5,600 |
Price Bid/Ask | 1.450 / 1.460 |
52w | 0.688 - 1.840 |
ROE | 6.28 |
P/E | 15 |
EPS | 9.36 |
DPS | |
DY | 0.00% |
NTA | 1.4900 |
P/B | 0.97 |
RPS | 601.06 |
PSR | 0 |
Market Cap | 371.1M |
Shares (mil) | 255.96 |
TopQ QoQ ConQ YoY | RTopQ RQoQ RConQ RYoY |
RSI(14) | Neutral 36.4 |
Stochastic(14) | Neutral 25.0 |
Average Volume | 744,000 |
Relative Volume | 0.8 |
==============================
ANCOM/ 4758
Journey to 1 ,000,000,000.00 / 1 billion RINGGIT MALAYSIAN -- market capitalisation
50 million PATAMI,( profit after tax and minority interests ) 20x P/E
1Billion- RM , market cap
[ 20x P/E is very conservative ; as Hextar/Global Berhad /5151-- (is assigned a 30x P/E by Public Bank- Research )
DETAILS SHOWING THE CALCULATIONS
40m PAT from Agrochemical business
20m PAT from Industrial & Petrochemical business
minus (10m) Corporate costs
= 50m PAT
(i) Current Ancom share base = 250m
(ii) ESOS = 20m
(iii) Issuance to Nylex minority = 30m
(iv)Total Ancom shares (post consolidation exercise )
= 300m
1B market cap/300m shares =
High | 1.490 |
Low | 1.430 |
Volume | 595,000 |
Volume (B/S) | 1,500 / 5,600 |
Price Bid/Ask | 1.450 / 1.460 |
52w | 0.688 - 1.840 |
ROE | 6.28 |
P/E | 15 |
EPS | 9.36 |
DPS | |
DY | 0.00% |
NTA | 1.4900 |
P/B | 0.97 |
RPS | 601.06 |
PSR | 0 |
Market Cap | 371.1M |
Shares (mil) | 255.96 |
TopQ QoQ ConQ YoY | RTopQ RQoQ RConQ RYoY |
RSI(14) | Neutral 36.4 |
Stochastic(14) | Neutral 25.0 |
Average Volume | 744,000 |
Relative Volume | 0.8 |
EPS | DPS | NTA | Revenue | P/L | Quarter | Q Date | Financial Year | Announced | QoQ% | YoY% | Report |
---|---|---|---|---|---|---|---|---|---|---|---|
3.19 | 0.000 | 1.4900 | 445.89m | 7.61m | 4 | 2021-05-31 | 31 May, 2021 | 2021-07-29 | 7.4% | 164.5% | View |
2.98 | 0.000 | 1.4600 | 389.20m | 7.08m | 3 | 2021-02-28 | 31 May, 2021 | 2021-04-28 | 14.4% | 4193.3% | View |
2.59 | 0.000 | 1.4300 | 357.27m | 6.19m | 2 | 2020-11-30 | 31 May, 2021 | 2021-01-26 | 102.3% | 393.6% | View |
1.28 | 0.000 | 1.4000 | 346.12m | 3.06m | 1 | 2020-08-31 | 31 May, 2021 |
Local agrochemical Hextar /5151 is given a P/E of 30 by PublicInvest.
What about other listed agrochem companies?
In the world of agrochemical companies that are listed
- Bayer Crop Science [P/E 52]
- Corteva [P/E 49]
- Sumitomo [P/E 59]
- Adama [P/E 59]
Average of P/E 50+ !!
Because they deal with FOOD SECURITY via crop protection, just like ANCOM.
Taking CURRENT FY patami of RM24m at various levels of P/E,
( as at 30 July 2021 )
P/E 25 = RM642m [ 73% upside ]
P/E 30 = RM767m [ 106% upside ]
P/E 35 = RM895m [ 141% upside ]
ANCOM's turnaround story has just begun, so the P/E may be gradually moving up. Plus, management forecast next year's results to be better than the current year's RM24 millions
,
ANCOM transforms into one of the LARGEST and PROFITABLE flagship integrated chemical group in Malaysia
(CCM 2.0?)
With this corporate consolidation exercise,
ANCOM is another step closer in realising its BILLION RINGGIT market cap target.
Finally...
NYLEX,
ANCOM,
will be a TWIN GEMS in the near future
=============================
Manufacturer of ethanol is FERMPRO wholly owned subsidiary of NYLEX.
The above picture showing the full client list of Entopest Environmental Services Sdn Bhd / subsidiary of Ancom Bhd
(official qualified licensed fumigator, a legal recognition awarded by the Malaysian - Ministry of Agriculture Awards the license upon the completion of intensive course on all aspects of fumigation requirements by the Ministry of Health.
Credentials - wide spectrum of clients (Tier One Clients) from:
i. Hypermarkets - Tesco, AEON, MYDIN, Giant.
ii. Banks - Maybank.
iii. Universities - Taylor's University, UPM, Garden International School.
iv. Corporate offices - Amway, Goodyear, KLK Oleo, Gamuda, Sunway, Gas Malaysia.
v. Hotels - Le Meriden, Renaissance Hotel, Grand Hyatt, The Mines Hotel.
vi. Restaurant Chains - Texas Chicken, Old Town, Secret Recipe.
vii. Logistics/Warehouses - TASCO/NYK Nippon Yusen Kaisha Group, Sanyku Group Japan.
viii. Medical & Healthcare - Ministry of Health Malaysia, Gleneagles Hospital, Caring, Guardian.
The above picture shows
Entopest is offering full sanitizing services that are compliant to the US FDA regulations for industrial and commercial usage that are highly effective against
Corona viruses.
The above picture shows a snapshot from one of Petronas stations in Malaysia.
In fact, all Petronas station toilets have
Entopest Hygiene sanitizing facilities.
In short, it caters for all segments of market - from domestic to commercial uses.
The Specific Answer: ANCOM/4758 & NYLEX/4944
SUMMARY
SEE RESEARCH
FOR NYLEX :
TARGET PRICES
RM 1.20 short term,
RM 1.50 mid term
=============================
FOR ANCOM:
TARGET PRICES
RM 2.00 short term,
RM 2.50 mid term
Key Abbreviations:
1. Ancom Berhad - is the holding company of Nylex (Malaysia). Berhad and Ancom Logistics Berhad, both are listed on the Bursa Malaysia Securities Berhad Main Board and ACE Market respectively.
2. Entopest Environmental Services Sdn Bhd (wholly-owned subsidiary of Ancom Berhad).
3. Fermpro Sdn Bhd (subsidiary of Nylex Berhad) Nylex Malaysia Berhad.
------------------------------
Thanks for reading and see you in the next post.
DISCLAIMER:IT IS NOT A BUY OR SELL CALL AND IS ONLY A PERSONAL OPINION, WRITTEN AS ARTICLE FOR SHARING PURPOSES TO KLSE COMMUNITY MEMBERS.
Investment involves risks, including possible loss of investment and other losses.
This article and charts are provided for information only and should not be construed as a solicitation to buy or sell any of the instruments mentioned herein.
The author may have positions in some of these instruments. The author shall not be responsible for any losses or profits resulting from investment decisions based on the use of the information contained herein. If investments and other professional advice is required, the services of a licensed professional person should be sought.
ISSUED BY SEE RESEARCH
(SENSING EAGLE EYES RESEARCH